Drugs / ABT-767
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01339650 | May 2011 → Nov 2017 | fallopian tube neoplasm, ovarian neoplasm, primary peritoneal carcinoma | AbbVie | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-767 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01339650 ↗ |
| Action | Inhibit | “ABT-767 is a potent oral inhibitor of the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2).” NCT01339650 ↗ |
| Route | Oral | “orally administered ABT-767” NCT01339650 ↗ |